Close Menu

In 10 years, NHGRI hopes to take DNA sequencers from the lab to the clinic, but some companies think 10 years isn't soon enough, says Forbes' Matthew Herper. Illumina's Jay Flatley has already talked about getting regulatory approval "to use his technology for medical purposes," Herper says. And even though regulatory approval — whether of the sequencers themselves or the interpretation of the sequence is unclear — is only the first hurdle.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.